Eintrag weiter verarbeiten
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy
Gespeichert in:
| Zeitschriftentitel: | Integrative Cancer Therapies |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Integrative Cancer Therapies, 15, 2016, 4, S. 467-477 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
SAGE Publications
|
| Schlagwörter: |
| author_facet |
Kim, Jongmin Cho, Chong-Kwan Yoo, Hwa-Seung Kim, Jongmin Cho, Chong-Kwan Yoo, Hwa-Seung |
|---|---|
| author |
Kim, Jongmin Cho, Chong-Kwan Yoo, Hwa-Seung |
| spellingShingle |
Kim, Jongmin Cho, Chong-Kwan Yoo, Hwa-Seung Integrative Cancer Therapies Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy Complementary and alternative medicine Oncology |
| author_sort |
kim, jongmin |
| spelling |
Kim, Jongmin Cho, Chong-Kwan Yoo, Hwa-Seung 1534-7354 1552-695X SAGE Publications Complementary and alternative medicine Oncology http://dx.doi.org/10.1177/1534735416639714 <jats:p> Objective. To investigate the clinical effect and the overall survival (OS) rate of patients with advanced non–small cell lung cancer (NSCLC) who have undergone Wheel Balance Cancer Therapy (WBCT). Methods. The cases of 33 patients with advanced NSCLC who were treated with WBCT at the East West Cancer Center (EWCC) between October 4, 2004, and October 3, 2013, without undergoing concurrent conventional treatment were analyzed. The Kaplan-Meier method was used to estimate the OS of the cases, and the median OS was calculated according to age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), conventional-treatment history, WBCT treatment duration, and histological tumor type. Results. The median OS of all patients was 31.1 (95% confidence interval [CI] = 3.5-58.7) months; the OS rates were 63.6% and 24.2% at years 1 and 2, respectively. The median OS rates of patients under and over 65 years were 45.2 (95% CI = 13.5-76.9) and 19.5 (95% CI = 7.1-31.8) months, respectively ( P = .189). The median OS rates of patients who received WBCT for >14 days but <28 days and those who received WBCT for ≥28 days were 16.2 (95% CI = 13.3-19.2) and 45.2 (95% CI = 14.4-76.0) months, respectively ( P = .437). The median OS rates of patients who had undergone prior conventional treatment and those who had not were 45.2 (95% CI = 9.1-81.3) and 3.9 (95% CI = unable to calculate) months, respectively ( P = .000). The median OS rates of patients with squamous cell carcinoma (SCC) and non-SCC lung cancer were 5.6 (95% CI = unable to calculate) and 45.2 (95% CI = 9.1-81.3) months, respectively ( P = .262). The median OS rate of patients with ECOG PS ≥3 was 14.3 (95% CI = 8.8-19.8) months; that of patients ECOG PS <3 could not be calculated. However, the mean OS rates of patients with ECOG PS <3 and with ECOG PS ≥3 were 85.7 (95% CI = 58.4-113.0) and 12.7 (95% CI = 8.5-16.9) months, respectively ( P = .000). No severe adverse events were encountered. Conclusions. Our study indicates that WBCT might be effective to prolong the length of survival for patients with advanced NSCLC who have previously undergone conventional treatment and have an ECOG PS <3. </jats:p> Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy Integrative Cancer Therapies |
| doi_str_mv |
10.1177/1534735416639714 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xNTM0NzM1NDE2NjM5NzE0 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xNTM0NzM1NDE2NjM5NzE0 |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
SAGE Publications, 2016 |
| imprint_str_mv |
SAGE Publications, 2016 |
| issn |
1534-7354 1552-695X |
| issn_str_mv |
1534-7354 1552-695X |
| language |
English |
| mega_collection |
SAGE Publications (CrossRef) |
| match_str |
kim2016survivalanalysisofadvancednonsmallcelllungcancerpatientstreatedbyusingwheelbalancecancertherapy |
| publishDateSort |
2016 |
| publisher |
SAGE Publications |
| recordtype |
ai |
| record_format |
ai |
| series |
Integrative Cancer Therapies |
| source_id |
49 |
| title |
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_unstemmed |
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_full |
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_fullStr |
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_full_unstemmed |
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_short |
Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_sort |
survival analysis of advanced non–small cell lung cancer patients treated by using wheel balance cancer therapy |
| topic |
Complementary and alternative medicine Oncology |
| url |
http://dx.doi.org/10.1177/1534735416639714 |
| publishDate |
2016 |
| physical |
467-477 |
| description |
<jats:p> Objective. To investigate the clinical effect and the overall survival (OS) rate of patients with advanced non–small cell lung cancer (NSCLC) who have undergone Wheel Balance Cancer Therapy (WBCT). Methods. The cases of 33 patients with advanced NSCLC who were treated with WBCT at the East West Cancer Center (EWCC) between October 4, 2004, and October 3, 2013, without undergoing concurrent conventional treatment were analyzed. The Kaplan-Meier method was used to estimate the OS of the cases, and the median OS was calculated according to age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), conventional-treatment history, WBCT treatment duration, and histological tumor type. Results. The median OS of all patients was 31.1 (95% confidence interval [CI] = 3.5-58.7) months; the OS rates were 63.6% and 24.2% at years 1 and 2, respectively. The median OS rates of patients under and over 65 years were 45.2 (95% CI = 13.5-76.9) and 19.5 (95% CI = 7.1-31.8) months, respectively ( P = .189). The median OS rates of patients who received WBCT for >14 days but <28 days and those who received WBCT for ≥28 days were 16.2 (95% CI = 13.3-19.2) and 45.2 (95% CI = 14.4-76.0) months, respectively ( P = .437). The median OS rates of patients who had undergone prior conventional treatment and those who had not were 45.2 (95% CI = 9.1-81.3) and 3.9 (95% CI = unable to calculate) months, respectively ( P = .000). The median OS rates of patients with squamous cell carcinoma (SCC) and non-SCC lung cancer were 5.6 (95% CI = unable to calculate) and 45.2 (95% CI = 9.1-81.3) months, respectively ( P = .262). The median OS rate of patients with ECOG PS ≥3 was 14.3 (95% CI = 8.8-19.8) months; that of patients ECOG PS <3 could not be calculated. However, the mean OS rates of patients with ECOG PS <3 and with ECOG PS ≥3 were 85.7 (95% CI = 58.4-113.0) and 12.7 (95% CI = 8.5-16.9) months, respectively ( P = .000). No severe adverse events were encountered. Conclusions. Our study indicates that WBCT might be effective to prolong the length of survival for patients with advanced NSCLC who have previously undergone conventional treatment and have an ECOG PS <3. </jats:p> |
| container_issue |
4 |
| container_start_page |
467 |
| container_title |
Integrative Cancer Therapies |
| container_volume |
15 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792338544663986181 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:33:24.532Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Survival+Analysis+of+Advanced+Non%E2%80%93Small+Cell+Lung+Cancer+Patients+Treated+by+Using+Wheel+Balance+Cancer+Therapy&rft.date=2016-12-01&genre=article&issn=1552-695X&volume=15&issue=4&spage=467&epage=477&pages=467-477&jtitle=Integrative+Cancer+Therapies&atitle=Survival+Analysis+of+Advanced+Non%E2%80%93Small+Cell+Lung+Cancer+Patients+Treated+by+Using+Wheel+Balance+Cancer+Therapy&aulast=Yoo&aufirst=Hwa-Seung&rft_id=info%3Adoi%2F10.1177%2F1534735416639714&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792338544663986181 |
| author | Kim, Jongmin, Cho, Chong-Kwan, Yoo, Hwa-Seung |
| author_facet | Kim, Jongmin, Cho, Chong-Kwan, Yoo, Hwa-Seung, Kim, Jongmin, Cho, Chong-Kwan, Yoo, Hwa-Seung |
| author_sort | kim, jongmin |
| container_issue | 4 |
| container_start_page | 467 |
| container_title | Integrative Cancer Therapies |
| container_volume | 15 |
| description | <jats:p> Objective. To investigate the clinical effect and the overall survival (OS) rate of patients with advanced non–small cell lung cancer (NSCLC) who have undergone Wheel Balance Cancer Therapy (WBCT). Methods. The cases of 33 patients with advanced NSCLC who were treated with WBCT at the East West Cancer Center (EWCC) between October 4, 2004, and October 3, 2013, without undergoing concurrent conventional treatment were analyzed. The Kaplan-Meier method was used to estimate the OS of the cases, and the median OS was calculated according to age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), conventional-treatment history, WBCT treatment duration, and histological tumor type. Results. The median OS of all patients was 31.1 (95% confidence interval [CI] = 3.5-58.7) months; the OS rates were 63.6% and 24.2% at years 1 and 2, respectively. The median OS rates of patients under and over 65 years were 45.2 (95% CI = 13.5-76.9) and 19.5 (95% CI = 7.1-31.8) months, respectively ( P = .189). The median OS rates of patients who received WBCT for >14 days but <28 days and those who received WBCT for ≥28 days were 16.2 (95% CI = 13.3-19.2) and 45.2 (95% CI = 14.4-76.0) months, respectively ( P = .437). The median OS rates of patients who had undergone prior conventional treatment and those who had not were 45.2 (95% CI = 9.1-81.3) and 3.9 (95% CI = unable to calculate) months, respectively ( P = .000). The median OS rates of patients with squamous cell carcinoma (SCC) and non-SCC lung cancer were 5.6 (95% CI = unable to calculate) and 45.2 (95% CI = 9.1-81.3) months, respectively ( P = .262). The median OS rate of patients with ECOG PS ≥3 was 14.3 (95% CI = 8.8-19.8) months; that of patients ECOG PS <3 could not be calculated. However, the mean OS rates of patients with ECOG PS <3 and with ECOG PS ≥3 were 85.7 (95% CI = 58.4-113.0) and 12.7 (95% CI = 8.5-16.9) months, respectively ( P = .000). No severe adverse events were encountered. Conclusions. Our study indicates that WBCT might be effective to prolong the length of survival for patients with advanced NSCLC who have previously undergone conventional treatment and have an ECOG PS <3. </jats:p> |
| doi_str_mv | 10.1177/1534735416639714 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xNTM0NzM1NDE2NjM5NzE0 |
| imprint | SAGE Publications, 2016 |
| imprint_str_mv | SAGE Publications, 2016 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 1534-7354, 1552-695X |
| issn_str_mv | 1534-7354, 1552-695X |
| language | English |
| last_indexed | 2024-03-01T15:33:24.532Z |
| match_str | kim2016survivalanalysisofadvancednonsmallcelllungcancerpatientstreatedbyusingwheelbalancecancertherapy |
| mega_collection | SAGE Publications (CrossRef) |
| physical | 467-477 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | SAGE Publications |
| record_format | ai |
| recordtype | ai |
| series | Integrative Cancer Therapies |
| source_id | 49 |
| spelling | Kim, Jongmin Cho, Chong-Kwan Yoo, Hwa-Seung 1534-7354 1552-695X SAGE Publications Complementary and alternative medicine Oncology http://dx.doi.org/10.1177/1534735416639714 <jats:p> Objective. To investigate the clinical effect and the overall survival (OS) rate of patients with advanced non–small cell lung cancer (NSCLC) who have undergone Wheel Balance Cancer Therapy (WBCT). Methods. The cases of 33 patients with advanced NSCLC who were treated with WBCT at the East West Cancer Center (EWCC) between October 4, 2004, and October 3, 2013, without undergoing concurrent conventional treatment were analyzed. The Kaplan-Meier method was used to estimate the OS of the cases, and the median OS was calculated according to age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), conventional-treatment history, WBCT treatment duration, and histological tumor type. Results. The median OS of all patients was 31.1 (95% confidence interval [CI] = 3.5-58.7) months; the OS rates were 63.6% and 24.2% at years 1 and 2, respectively. The median OS rates of patients under and over 65 years were 45.2 (95% CI = 13.5-76.9) and 19.5 (95% CI = 7.1-31.8) months, respectively ( P = .189). The median OS rates of patients who received WBCT for >14 days but <28 days and those who received WBCT for ≥28 days were 16.2 (95% CI = 13.3-19.2) and 45.2 (95% CI = 14.4-76.0) months, respectively ( P = .437). The median OS rates of patients who had undergone prior conventional treatment and those who had not were 45.2 (95% CI = 9.1-81.3) and 3.9 (95% CI = unable to calculate) months, respectively ( P = .000). The median OS rates of patients with squamous cell carcinoma (SCC) and non-SCC lung cancer were 5.6 (95% CI = unable to calculate) and 45.2 (95% CI = 9.1-81.3) months, respectively ( P = .262). The median OS rate of patients with ECOG PS ≥3 was 14.3 (95% CI = 8.8-19.8) months; that of patients ECOG PS <3 could not be calculated. However, the mean OS rates of patients with ECOG PS <3 and with ECOG PS ≥3 were 85.7 (95% CI = 58.4-113.0) and 12.7 (95% CI = 8.5-16.9) months, respectively ( P = .000). No severe adverse events were encountered. Conclusions. Our study indicates that WBCT might be effective to prolong the length of survival for patients with advanced NSCLC who have previously undergone conventional treatment and have an ECOG PS <3. </jats:p> Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy Integrative Cancer Therapies |
| spellingShingle | Kim, Jongmin, Cho, Chong-Kwan, Yoo, Hwa-Seung, Integrative Cancer Therapies, Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy, Complementary and alternative medicine, Oncology |
| title | Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_full | Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_fullStr | Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_full_unstemmed | Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_short | Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| title_sort | survival analysis of advanced non–small cell lung cancer patients treated by using wheel balance cancer therapy |
| title_unstemmed | Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy |
| topic | Complementary and alternative medicine, Oncology |
| url | http://dx.doi.org/10.1177/1534735416639714 |